Shots:

• Janssen partnered with Emergent to develop more than a billion doses of a COVID-19 vaccine candidate- as it anticipates scaling up global manufacturing of its potential treatment. The agreement valued ~135M
• Emergent will provide manufacturing services with its molecule-to-market CDMO offering- beginning in 2020 and will reserve operations capacity to support manufacturing of J&J’s COVID-19 vaccine candidate leveraging Janssen’s AdVac and PER.C6 technologies initiating in 2021
• J&J has initiated preparations for clinical vaccine production at its facility in the Netherlands- intending to commence P-I clinical studies of its vaccine candidate in Sept’2020

Click here ­to­ read full press release/ article 

Ref: J&J | Image:Janssen